GRI Bio, Inc. (GRI)
$1.74+3.57%Close
SELLCRISIS · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $156,308
- Beta
- -0.61
- P/E (TTM)
- -0.04
- Short % float
- 77.30%
- Days to cover
- 1.0
- SI change
- -40.7%
- 1W
- -11.22%
- 1M
- -10.31%
- vs SPY 1W
- -12.38%
- vs SPY 1M
- -13.30%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on GRI?
- LOPJLB’s latest quantitative signal on GRI Bio, Inc. (GRI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is GRI in?
- GRI Bio, Inc. (GRI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does GRI Bio, Inc. (GRI) do?
- GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lun…